Quantinno Capital Management LP Purchases 8,149 Shares of Solventum Co. (NYSE:SOLV)

Quantinno Capital Management LP increased its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 126.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,575 shares of the company's stock after purchasing an additional 8,149 shares during the quarter. Quantinno Capital Management LP's holdings in Solventum were worth $963,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Clarity Asset Management Inc. bought a new position in Solventum during the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new stake in shares of Solventum in the 4th quarter valued at approximately $26,000. Crews Bank & Trust bought a new stake in shares of Solventum in the 4th quarter valued at approximately $32,000. Colonial Trust Co SC lifted its stake in shares of Solventum by 240.7% in the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after purchasing an additional 361 shares during the last quarter. Finally, Synergy Asset Management LLC bought a new stake in shares of Solventum in the 4th quarter valued at approximately $35,000.

Solventum Trading Up 2.4%

Shares of SOLV stock traded up $1.68 on Tuesday, reaching $72.49. 794,932 shares of the company's stock were exchanged, compared to its average volume of 1,244,979. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $12.54 billion and a PE ratio of 33.56. The company's fifty day simple moving average is $69.60 and its 200 day simple moving average is $71.25.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.19 by $0.15. The firm had revenue of $2.07 billion for the quarter, compared to analysts' expectations of $2.02 billion. The company's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.08 earnings per share. As a group, analysts forecast that Solventum Co. will post 6.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SOLV. The Goldman Sachs Group raised their price objective on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. Mizuho raised their price objective on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Morgan Stanley raised their price objective on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. Finally, Piper Sandler raised Solventum from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $80.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.